Development of ^<99m>Tc-complexes for imaging cancer metastasis
用于癌症转移成像的^<99m>Tc复合物的开发
基本信息
- 批准号:09672190
- 负责人:
- 金额:$ 1.92万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1997
- 资助国家:日本
- 起止时间:1997 至 1998
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We planed to develope the imaging agent for cancer metastasis by the two approaches as followes :(1) Production of ^<99m>Tc-labded compounds by the introduction of ^<99m>Tc-complexes to the antibody or polypeptide that shows high affinity for the antigen or receptor on cell membrane of primary canncer and the importantfactor for angiogenesis(2) Development of ^<99m>Tc-coinplexes that show high affinity for tumor.Since ^<99m>Tc-iagnostic agents essetially contains the ^<99m>Tc by the coordinate bond, the behavior of ^<99m>Tc in vivo is very influenced by the equilibrium state involving the ligand and ^<99m>Tc. Accordingly, the present ^<99m>Tc-radiopharmaceuticals have developed on the base of the strategy described above (1), namely many researchers developed the various ligand systems that form the higly stable ^<99m>Tc-complexes. However, the ligand system availabe for the clinical use has not been completed.On the other hand, though it is known that seine polynucleus metal complexes show high affinity for tumor, the systematic research has never been carried out.In this study, We selected the two ligand systems to perform the duvelopment of ^<99m>Tc-complexes for imaging cancer metastasisboth by the two way. One is hydroxamamide ligand system which form stable ^<99m>Tc-complex. The other is hydroxamica acid ligand system which have the possibility for the formation of the polynucleous ^<99m>Tc-complexes. The difference in ligand system resulted in the change of the properties of ^<99m>Tc-complex and the behavior of ^<99m>Tc in vivo.
We planed to develope the imaging agent for cancer metastasis by the two approaches as followes :(1) Production of ^<99m>Tc-labded compounds by the introduction of ^<99m>Tc-complexes to the antibody or polypeptide that shows high affinity for the antigen or receptor on cell membrane of primary canncer and the importantfactor for angiogenesis(2) Development of ^<99m> tc-coinplexes对肿瘤表现出很高的亲和力。 ^<99m> tc-iagnostic ventents在本文上通过坐标键包含 ^<99m> tc,体内 ^<99m> tc tc的行为受到了均衡状态的影响,受到了Ligilibrium的均衡状态,并受到LIGAND的均衡状态和 ^99m> tc的均衡状态。因此,目前的 ^<99m> tc-radiopharmaceuticals已在上述策略的基础上开发了(1),即许多研究人员开发了形成稳定稳定的 ^<99m> tc-compelxes的各种配体系统。 However, the ligand system availabe for the clinical use has not been completed.On the other hand, though it is known that seine polynucleus metal complexes show high affinity for tumor, the systematic research has never been carried out.In this study, We selected the two ligand systems to perform the duvelopment of ^<99m>Tc-complexes for imaging cancer metastasisboth by the two way.一个是羟胺胺配体系统,形成稳定的 ^<99m> Tc-complex。另一个是羟基酸配体系统,它具有形成多核 ^<99m> tc-complexes的可能性。配体系统的差异导致 ^<99m> tc-complex的性质变化以及体内 ^<99m> tc的行为。
项目成果
期刊论文数量(17)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
許 楽村: "Bis(Hydroxamamide)-Based Bifunctional Chelating Agent for ^<99m>Tc Labeling of Polypeptides and Peptides." Bioconjugate Chem.10巻. 9-17 (1999)
Lecun Xu:“基于双(羟肟酰胺)的双功能螯合剂,用于多肽和肽的^ 99m Tc标记。” Bioconjugate Chem. Vol. 10. 9-17 (1999)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
許 楽村: "Bis(Hydroxamamide)-Based Bifunctional Chelating Agent for^<99m>Tc Labeling of Polypeptides and Peptides." Bioconjugate Chem.10巻. 9-17 (1999)
Lecun Xu:“基于双(羟肟酰胺)的双功能螯合剂,用于多肽和肽的^ 99m Tc标记。” Bioconjugate Chem. Vol. 10. 9-17 (1999)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
小野 正博: "Intracellular Metabolic Fate of Radioactivity after Injection of ^<99III>Tc-Labeled Hydrazino Nicotinamide Derivatized Polypeptides." Bioconjugate Chem.(in press). (1999)
Masahiro Ono:“注射 ^<99III>Tc 标记的肼基烟酰胺衍生多肽后放射性的细胞内代谢结果。”(正在出版)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Nakayama M: "Hydroxamamide as a chelating moiety for the preparation of ^<99m>Tc-radiopharmaceuticals III.Characterization of ^<99m>Tc-hydroxamamides." Appl.Rad, Isotop.48. 571-577 (1997)
Nakayama M:“羟肟酰胺作为螯合部分用于制备^ 99m> Tc-放射性药物III。^ 99m> Tc-羟肟酰胺的表征。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ono M: "Intracellular Metabolic Fate of Radioactivity after Injection of ^<99m>Tc-Labeled Hydrazino Nicotinamide Derivatized Polypeptides." Bioconjugate Chem.(in press).
Ono M:“注射^<99m>Tc标记的肼基烟酰胺衍生多肽后放射性的细胞内代谢命运。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAKAYAMA Morio其他文献
NAKAYAMA Morio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAKAYAMA Morio', 18)}}的其他基金
Development of a unified producing system for various 68Ga-radiopharmaceuticals based on the characteristics of novel 68Ge/68Ga generator.
基于新型68Ge/68Ga发生器的特点,开发了多种68Ga放射性药物的统一生产系统。
- 批准号:
16H05392 - 财政年份:2016
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of multimodal imaging probes targeting survivin.
开发针对生存素的多模态成像探针。
- 批准号:
16K15585 - 财政年份:2016
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of molecular probe for SPECT imaging of amyloid in the brain
开发脑部淀粉样蛋白 SPECT 成像分子探针
- 批准号:
21390348 - 财政年份:2009
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of production-system of PET imaging agents without cyclotron.
开发无回旋加速器的PET显像剂生产系统。
- 批准号:
18390015 - 财政年份:2006
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
In Vivo Imaging of β-Amyloid Plaques in Alzheimer's Disease Brains.
阿尔茨海默病大脑中 β-淀粉样斑块的体内成像。
- 批准号:
15390014 - 财政年份:2003
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Construction of lipid bilayer membrane on ion-exchange resin surface and the application as separation material
离子交换树脂表面脂质双层膜的构建及其作为分离材料的应用
- 批准号:
11672146 - 财政年份:1999
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Preparation of ^<99m>Tc radiopharmaceuticals using macroreticular Sn (II) complex
大网状Sn(II)络合物制备^<99m>Tc放射性药物
- 批准号:
04557104 - 财政年份:1992
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
Developement of New Polymer Membranes for Separation
新型聚合物分离膜的开发
- 批准号:
60550644 - 财政年份:1985
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似国自然基金
可代谢调控弱碱性钠盐纳米材料的控制合成及其在增强癌症免疫治疗中的应用
- 批准号:52372273
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
纤毛发生相关激酶-1在癌症进展和耐药中的作用与机制研究
- 批准号:82373161
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
药效关联的癌症单细胞亚群识别与精准联合医疗研究
- 批准号:32370702
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
面向癌症驱动因子识别及其调控作用预测的因果推断方法研究
- 批准号:62372210
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
基于癌症Hallmark的高性能可解释ICI药物响应预测模型研究
- 批准号:62372134
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
相似海外基金
Development of nanoparticulate solution for cancer treatment by breakup of tumor extracellular hydroxyapatite: a new paradigm
通过分解肿瘤细胞外羟基磷灰石来开发用于癌症治疗的纳米颗粒溶液:一个新范例
- 批准号:
10218793 - 财政年份:2021
- 资助金额:
$ 1.92万 - 项目类别:
SBIR PHASE I TOPIC 392: TARGETED RADIONUCLIDE THERAPY OF METASTATIC LIVER CANCER: PATIENT SPECIFIC OPTIMIZATION
SBIR 第一阶段主题 392:转移性肝癌的靶向放射性核素治疗:针对患者的优化
- 批准号:
10032840 - 财政年份:2019
- 资助金额:
$ 1.92万 - 项目类别:
Contrast Ultrasound Detection of Sentinel Lymph Nodes in Breast Cancer Patients
乳腺癌患者前哨淋巴结的超声造影检测
- 批准号:
9001939 - 财政年份:2015
- 资助金额:
$ 1.92万 - 项目类别:
PET Enabled Y-90 Microspheres for Radioembolization of Liver Tumors
用于肝脏肿瘤放射栓塞的 PET 启用 Y-90 微球
- 批准号:
10453651 - 财政年份:2012
- 资助金额:
$ 1.92万 - 项目类别:
PET Enabled Y-90 Microspheres for Radioembolization of Liver Tumors
用于肝脏肿瘤放射栓塞的 PET 启用 Y-90 微球
- 批准号:
10250747 - 财政年份:2012
- 资助金额:
$ 1.92万 - 项目类别: